Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

1.510 +0.080 (+5.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,068,521
Open 1.400
Bid (Size) 1.450 (1)
Ask (Size) 1.580 (20)
Prev. Close 1.430
Today's Range 1.395 - 1.599
52wk Range 1.085 - 7.660
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Thursday?
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill

Performance

YTD
-58.7%
-58.7%
1 Month
+13.5%
+13.5%
3 Month
+5.2%
+5.2%
6 Month
-58.1%
-58.1%
1 Year
-68.9%
-68.9%

More News

Read More
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in Upcoming March Investor Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
AT&T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
From C4 Therapeutics, Inc.
Via GlobeNewswire
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in Upcoming September Investor Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
From C4 Therapeutics, Inc.
Via GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace

Frequently Asked Questions

Is C4 Therapeutics, Inc. - Common Stock publicly traded?
Yes, C4 Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does C4 Therapeutics, Inc. - Common Stock trade on?
C4 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for C4 Therapeutics, Inc. - Common Stock?
The ticker symbol for C4 Therapeutics, Inc. - Common Stock is CCCC on the Nasdaq Stock Market
What is the current price of C4 Therapeutics, Inc. - Common Stock?
The current price of C4 Therapeutics, Inc. - Common Stock is 1.510
When was C4 Therapeutics, Inc. - Common Stock last traded?
The last trade of C4 Therapeutics, Inc. - Common Stock was at 07/01/25 04:00 PM ET
What is the market capitalization of C4 Therapeutics, Inc. - Common Stock?
The market capitalization of C4 Therapeutics, Inc. - Common Stock is 73.68M
How many shares of C4 Therapeutics, Inc. - Common Stock are outstanding?
C4 Therapeutics, Inc. - Common Stock has 74M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.